B of A Securities Maintains Buy on Denali Therapeutics, Raises Price Target to $29
Portfolio Pulse from Benzinga Newsdesk
B of A Securities has maintained its Buy rating on Denali Therapeutics and raised the price target from $25 to $29, indicating confidence in the company's future performance.
September 04, 2024 | 11:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities has reaffirmed its Buy rating on Denali Therapeutics and increased the price target from $25 to $29, suggesting a positive outlook for the company's stock.
The reaffirmation of the Buy rating and the increase in the price target by B of A Securities indicates a strong positive sentiment towards Denali Therapeutics. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100